Review

You have free access to this content

Antidepressant use in pregnancy: a critical review focused on risks and controversies

N. Byatt^1,*,
K. M. Deligiannidis²,
M. P. Freeman³

Article first published online: 14 DEC 2012

DOI: 10.1111/acps.12042

Issue

Acta Psychiatrica Scandinavica

Volume 127, Issue 2, pages 94–114, February 2013

Additional Information

How to Cite

Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Author Information

¹
Psychiatry and Obstetrics & Gynecology, Psychosomatic Medicine, Women's Mental Health, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, USA
²
Psychiatry and Obstetrics & Gynecology, Depression Specialty Clinic, Women's Mental Health Specialty Clinic, Center for Psychopharmacologic Research and Treatment, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, USA
³
Psychiatry, Perinatal and Reproductive Psychiatry Program, Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA

^* Nancy Byatt, Psychiatry and Obstetrics & Gynecology, Psychosomatic Medicine, Women's Mental Health, University of Massachusetts Medical School/UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, MA 01655, USA.
E-mail: nancy.byatt@umassmemorial.org

Publication History

Issue published online: 9 JAN 2013
Article first published online: 14 DEC 2012
Manuscript Accepted: 10 OCT 2012

ARTICLE TOOLS

View Full Article (HTML) Get PDF (184K)

References

1
Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 2008;65:805–815.
2
Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005;106:1071–1083.
3
Borri C, Mauri M, Oppo A et al. Axis I psychopathology and functional impairment at the third month of pregnancy: results from the perinatal depression-research and screening unit (PND-ReScU) study. J Clin Psychiatry 2008;69:1617–1624.
4
Reck C, Struben K, Backenstrass M et al. Prevalence, onset and comorbidity of postpartum anxiety and depressive disorders. Acta Psychiatr Scand 2008;118:459–468.
Direct Link:
5
Bodnar LM, Wisner KL, Moses-Kolko E, Sit DK, Hanusa BH. Prepregnancy body mass index, gestational weight gain, and the likelihood of major depressive disorder during pregnancy. J Clin Psychiatry 2009;70:1290–1296.
- CrossRef,
- Web of Science® Times Cited: 8
6
Flynn HA, Chermack ST. Prenatal alcohol use: the role of lifetime problems with alcohol, drugs, depression, and violence. J Stud Alcohol Drugs 2008;69:500–509.
- PubMed,
- Web of Science® Times Cited: 10
7
Cripe SM, Frederick IO, Qiu C, Williams MA. Risk of preterm delivery and hypertensive disorders of pregnancy in relation to maternal co-morbid mood and migraine disorders during pregnancy. Paediatr Perinat Epidemiol 2011;25:116–123.
Direct Link:
8
Wisner KL, Zarin DA, Holmboe ES et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000;157:1933–1940.
9
Wadhwa PD, Sandman CA, Porto M, Dunkel-Schetter C, Garite TJ. The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investigation. Am J Obstet Gynecol 1993;169:858–865.
10
Istvan J. Stress, anxiety, and birth outcomes: a critical review of the evidence. Psychol Bull 1986;100:331–348.
11
Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010;67:1012–1024.
- CrossRef,
- Web of Science® Times Cited: 52
12
Suri R, Altshuler LA, Mintz J. Depression and the decision to abort. Am J Psychiatry 2004;161:1502.
13
Gotlib IH, Whiffen VE, Wallace PM, Mount JH. Prospective investigation of postpartum depression: factors involved in onset and recovery. J Abnorm Psychol 1991;100:122–132.
14
Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005;162:79–91.
15
Chung TK, Lau TK, Yip AS, Chiu HF, Lee DT. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001;63:830–834.
16
Forman DR, O'hara MW, Stuart S, Gorman LL, Larsen KE, Coy KC. Effective treatment for postpartum depression is not sufficient to improve the developing mother-child relationship. Dev Psychopathol 2007;19:585–602.
17
Britton JR. Infant temperament and maternal anxiety and depressed mood in the early postpartum period. Women Health 2011;51:55–71.
- CrossRef,
- Web of Science® Times Cited: 2
18
Sohr-Preston SL, Scaramella LV. Implications of timing of maternal depressive symptoms for early cognitive and language development. Clin Child Fam Psychol Rev 2006;9:65–83.
19
Downey G, Coyne JC. Children of depressed parents: an integrative review. Psychol Bull 1990;108:50–76.
20
Deave T, Heron J, Evans J, Emond A. The impact of maternal depression in pregnancy on early child development. BJOG 2008;115:1043–1051.
Direct Link:
21
Paulson JF, Keefe HA, Leiferman JA. Early parental depression and child language development. J Child Psychol Psychiatry 2009;50:254–262.
Direct Link:
22
Pilowsky DJ, Wickramaratne PJ, Rush AJ et al. Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry 2006;67:126–136.
23
Weissman MM, Pilowsky DJ, Wickramaratne PJ et al. Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA 2006;295:1389–1398.
24
Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health 2005;8:77–87.
25
Lobel M, Cannella DL, Graham JE, Devincent C, Schneider J, Meyer BA. Pregnancy-specific stress, prenatal health behaviors, and birth outcomes. Health Psychol 2008;27:604–615.
26
Beydoun H, Saftlas AF. Physical and mental health outcomes of prenatal maternal stress in human and animal studies: a review of recent evidence. Paediatr Perinat Epidemiol 2008;22:438–466.
Direct Link:
27
Buss C, Davis EP, Muftuler LT, Head K, Sandman CA. High pregnancy anxiety during mid-gestation is associated with decreased gray matter density in 6-9-year-old children. Psychoneuroendocrinology 2010;35:141–153.
- CrossRef,
- Web of Science® Times Cited: 26
28
Cohen LS, Altshuler LL, Harlow BL et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499–507.
29
Bennett IM, Marcus SC, Palmer SC, Coyne JC. Pregnancy-related discontinuation of antidepressants and depression care visits among Medicaid recipients. Psychiatr Serv 2010;61:386–391.
- CrossRef,
- Web of Science® Times Cited: 5
30
Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 2005;39:803–809.
31
Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol 2006;22:571–575.
32
Einarson A, Fatoye B, Sarkar M et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728–1730.
33
Einarson A, Choi J, Einarson TR, Koren G. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J Obstet Gynaecol Can 2009;31:452–456.
- PubMed
34
Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 2010;182:1031–1037.
- CrossRef,
- Web of Science® Times Cited: 29
35
Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010–1015.
36
Kulin NA, Pastuszak A, Sage SR et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609–610.
37
Chun-Fai-Chan B, Koren G, Fayez I et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005;192:932–936.
38
Yaris F, Kadioglu M, Kesim M et al. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol 2004;19:235–238.
39
Djulus J, Koren G, Einarson TR et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006;67:1280–1284.
40
Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312–316.
- CrossRef,
- Web of Science® Times Cited: 110
41
Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723–1733.
42
Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009;163:949–954.
- CrossRef,
- Web of Science® Times Cited: 41
43
Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055–2061.
44
Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007;164:1206–1213.
45
Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011;68:1104–1112.
- CrossRef,
- Web of Science® Times Cited: 20
46
Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011;128:1–9.
47
Rynn L, Cragan J, Correa A. Update on overall prevalence of major birth defects–Atlanta, Georgia, 1978–2005. MMWR Morb Mortal Wkly Rep 2008;57:1–5.
- PubMed
48
Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002;39:1890–1900.
49
Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 2008;153:807–813.
50
Kallen B, Nilsson E, Olausson PO. Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records. Eur J Clin Pharmacol 2011;67:839–845.
- CrossRef,
- Web of Science® Times Cited: 4
51
Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301–308.
Direct Link:
52
Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2010;121:471–479.
Direct Link:
53
Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289–1296.
54
Pastuszak A, Schick-Boschetto B, Zuber C et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246–2248.
55
Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188:812–815.
56
Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89:713–718.
57
Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503–508.
58
Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 2005;193:2004–2009.
59
Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005;25:59–73.
60
Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684–2692.
61
Merlob P, Birk E, Sirota L et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009;85:837–841.
Direct Link:
62
Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675–2683.
63
Birndorf CA, Madden A, Portera L, Leon AC. Psychiatric symptoms, functional impairment, and receptivity toward mental health treatment among obstetrical patients. Int J Psychiatry Med 2001;31:355–365.
64
Wogelius P, Norgaard M, Gislum M et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701–704.
65
Diav-Citrin O, Shechtman S, Weinbaum D et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66:695–705.
66
Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1075–1085.
Direct Link:
67
Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ 2005;173:1320–1321.
68
Einarson A, Koren G. Counseling pregnant women treated with paroxetine. Concern about cardiac malformations. Can Fam Physician 2006;52:593–594.
- PubMed,
- Web of Science® Times Cited: 6
69
Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80:18–27.
Direct Link:
70
Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88:159–170.
Direct Link:
71
Bar-Oz B, Einarson T, Einarson A et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007;29:918–926.
72
Bakker MK, Kerstjens-Frederikse WS, Buys CH, De Walle HE, De Jong-Van Den Berg LT. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010;88:94–100.
- CAS,
- Web of Science® Times Cited: 21
73
Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118:111–120.
- CrossRef,
- Web of Science® Times Cited: 17
74
Einarson A, Pistelli A, Desantis M et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008;165:749–752.
75
Gentile S, Bellantuono C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. J Clin Psychiatry 2009;70:414–422.
76
Bakker MK, De Walle HE, Wilffert B, De Jong-Van Den Berg LT. Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. Pharmacoepidemiol Drug Saf 2010;19:808–813.
Direct Link:
77
Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68–76.
Direct Link:
78
Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29–36.
79
Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
- CrossRef,
- Web of Science® Times Cited: 57
80
Wen SW, Yang Q, Garner P et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194:961–966.
81
Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009;54:242–246.
- PubMed,
- Web of Science® Times Cited: 27
82
Einarson A, Choi J, Koren G, Einarson T. Outcomes of infants exposed to multiple antidepressants during pregnancy: results of a cohort study. J Popul Ther Clin Pharmacol 2011;18:e390–e396.
- CAS
83
Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008;192:344–350.
84
Wisner KL, Sit DK, Hanusa BH et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009;166:557–566.
85
Klieger-Grossmann C, Weitzner B, Panchaud A et al. Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study. J Clin Pharmacol 2011;52:766–70.
- Web of Science® Times Cited: 2
86
Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000;30:89–94.
87
Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharma-coepidemiol Drug Saf 2005;14:823–827.
Direct Link:
88
O'brien L, Einarson TR, Sarkar M, Einarson A, Koren G. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 2008;30:696–701.
- PubMed
89
Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007;27:607–613.
- CrossRef,
- Web of Science® Times Cited: 29
90
Einarson A, Bonari L, Voyer-Lavigne S et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003;48:106–110.
- PubMed,
- Web of Science® Times Cited: 28
91
GlaxoSmithKline. The Bupropion Pregnancy Registry Final Report. 2008; Available from: http://pregnancyregistry.gsk.com/documents/bup_report_final_2008.pdf
92
Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010;203:52.e1–6.
93
Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:474–484.
Direct Link:
94
Webster PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973;2:318–319.
95
Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372–2383.
96
Nordeng H, Ystrom E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol 2010;66:207–214.
- CrossRef,
- Web of Science® Times Cited: 12
97
Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1993;92:721–722.
98
Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry 1997;171:391–392.
99
Nijhuis IJ, Kok-Van Rooij GW, Bosschaart AN. Withdrawal reactions of a premature neonate after maternal use of paroxetine. Arch Dis Child Fetal Neonatal Ed 2001;84:F77.
100
Sanz EJ, De-Las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482–487.
101
Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003;60:720–726.
102
Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129–1132.
103
Alehan F, Saygi S, Tarcan A, Gurakan B. Prolonged neonatal complications after in utero exposure to fluoxetine. J Matern Fetal Neonatal Med. 2008;21:921–923.
104
Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004;65:230–237.
105
Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898–906.
106
Knoppert DC, Nimkar R, Principi T, Yuen D. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels. Ther Drug Monit 2006;28:5–7.
107
Kwon P, Lefkowitz W. Poor neonatal adaptation in term infant. Fluoxetine toxicity. Pediatr Ann 2008;37:131–133.
108
Mhanna MJ, Bennet JB II, Izatt SD. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 1997;100:158–159.
109
Mohan CG, Moore JJ. Fluoxetine toxicity in a preterm infant. J Perinatol 2000;20:445–446.
- CrossRef,
- CAS
110
Anbu AT, Theodore A. Fluoxetine withdrawal syndrome in the newborn. Indian Pediatr 2006;43:66–69.
- PubMed,
- Web of Science® Times Cited: 2
111
Kent LS, Laidlaw JD. Suspected congenital sertraline dependence. Br J Psychiatry 1995;167:412–413.
112
Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol 2008;28:334–339.
113
Herbst F, Gortner L. [Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy?]. Z Geburtshilfe Neonatol 2003;207:232–234.
- PubMed,
- CAS
114
De Moor RA, Mourad L, Ter Haar J, Egberts AC. [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy]. Ned Tijdschr Geneeskd 2003;147:1370–1372.
- PubMed,
- CAS
115
Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000;48:996–1000.
116
Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173–176.
117
Ferreira E, Carceller AM, Agogue C et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007;119:52–59.
118
Galbally M, Lewis AJ, Lum J, Buist A. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 2009;43:846–854.
- CrossRef,
- Web of Science® Times Cited: 18
119
Suri R, Altshuler L, Hendrick V, Rasgon N, Lee E, Mintz J. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 2004;7:193–200.
- CrossRef,
- PubMed,
- CAS
120
Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008;115:283–289.
Direct Link:
121
Hibbard JU, Wilkins I, Sun L et al. Respiratory morbidity in late preterm births. JAMA 2010;304:419–425.
122
Administration US Food and Drug Administration. FDA Medwatch Drug Alert on Effexor (venlafaxine HCL) and Effexor XR (venlafaxine HCL) 2004 [cited 2011 12/22/11]; Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154975.htm.
123
Hernandez-Martinez C, Arija V, Balaguer A, Cavalle P, Canals J. Do the emotional states of pregnant women affect neonatal behaviour? Early Hum Dev [Research Support, Non-U.S. Govt]. 2008;84:745–750.
124
Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med 2010;11:S79–S84.
- CrossRef,
- Web of Science® Times Cited: 11
125
The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). J Pediatr 2000;136:611–617.
- CrossRef,
- PubMed
126
Davidson D, Barefield ES, Kattwinkel J et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998;101:325–334.
127
Greenough A, Khetriwal B. Pulmonary hypertension in the newborn. Paediatr Respir Rev 2005;6:111–116.
- CrossRef,
- PubMed
128
Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiatry 2012;169:134–40.
- CrossRef,
- Web of Science® Times Cited: 5
129
Group NINOS. Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). J Pediatr 2000;136:611–617.
- CrossRef,
- PubMed
130
Koren G, Boucher N. Adverse effects in neonates exposed to SSRIs and SNRI in late gestation–Motherisk Update 2008. Can J Clin Pharmacol 2009;16:e66–e67.
- PubMed
131
Boucher N, Koren G, Beaulac-Baillargeon L. Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit 2009;31:404–409.
132
Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008;192:338–343.
133
Eddahibi S, Raffestin B, Hamon M, Adnot S. Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med 2002;139:194–201.
134
Fornaro E, Li D, Pan J, Belik J. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 2007;176:1035–1040.
135
Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 2005;39:492–503.
Direct Link:
136
Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141–1150.
137
Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, Simpson EM. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008;13:65–73.
138
Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579–587.
139
Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008;17:801–806.
Direct Link:
140
Heritage CK, Cunningham MD. Association of elective repeat cesarean delivery and persistent pulmonary hypertension of the newborn. Am J Obstet Gynecol 1985;152:627–629.
141
Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007;120:e272–e282.
142
Kieler H, Artama M, Engeland A et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2011;344:d8012.
143
Andrade SE, Mcphillips H, Loren D et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009;18:246–252.
Direct Link:
144
Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009;84:23–27.
145
Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2010;28:19–24.
- CrossRef,
- Web of Science® Times Cited: 15
146
Administration USFAD. FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. 12/4/11 ed2011.
147
Keszler M, Carbone MT, Cox C, Schumacher RE. Severe respiratory failure after elective repeat cesarean delivery: a potentially preventable condition leading to extracorporeal membrane oxygenation. Pediatrics 1992;89:670–672.
148
Levine EM, Ghai V, Barton JJ, Strom CM. Mode of delivery and risk of respiratory diseases in newborns. Obstet Gynecol 2001;97:439–442.
149
Reece EA, Moya F, Yazigi R, Holford T, Duncan C, Ehrenkranz RA. Persistent pulmonary hypertension: assessment of perinatal risk factors. Obstet Gynecol 1987;70:696–700.
150
Gentile S. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects. Acta Psychiatr Scand. [Review]. 2011;123:266–275.
Direct Link:
151
US Food and Drug Administration. Pregnancy and Drug Labeling 2008 [cited 2012 11/6/12]; Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm.
152
Nulman I, Rovet J, Stewart DE et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159:1889–1895.
153
Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008;69:652–658.
154
Hostetter A, Stowe ZN, Strader JRJR, Mclaughlin E, Llewellyn A. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000;11:51–57.
Direct Link:
155
Yonkers KA, Wisner KL, Stewart DE et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31:403–413.
- CrossRef,
- Web of Science® Times Cited: 56
156
Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368–375.
157
Rampono J, Simmer K, Ilett KF et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009;42:95–100.
158
Suri R, Hellemann G, Stowe ZN, Cohen LS, Aquino A, Altshuler LL. A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. J Clin Psychiatry 2011;72:1002–1007.
- CrossRef,
- Web of Science® Times Cited: 2
159
Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. J Clin Psychiatry 2011;72:994–1001.
- CrossRef,
- Web of Science® Times Cited: 1
160
Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011;28:19–24.
- CrossRef,
- Web of Science® Times Cited: 15

View Full Article (HTML) Get PDF (184K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Antidepressant use in pregnancy: a critical review focused on risks and controversies

Acta Psychiatrica Scandinavica

How to Cite

Author Information

Publication History

ARTICLE TOOLS

References

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Antidepressant use in pregnancy: a critical review focused on risks and controversies

Acta Psychiatrica Scandinavica

How to Cite

Author Information

Publication History

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

References

More content like this